Xenetic Biosciences Inc Cash Flow Conversion Efficiency
Xenetic Biosciences Inc cash flow conversion efficiency. Based on the latest financial reports, Xenetic Biosciences Inc (XBIO) has a cash flow conversion efficiency ratio of -0.144x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-875.49K) by net assets ($6.07 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Xenetic Biosciences Inc (2012–2025)
Cash flow conversion efficiency of Xenetic Biosciences Inc from 2012 to 2025. This chart illustrates how Xenetic Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Xenetic Biosciences Inc stock price for real-time trading data and today's change.
Xenetic Biosciences Inc Cash Flow Conversion Ratio Explained
Xenetic Biosciences Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Xenetic Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Xenetic Biosciences Inc ranked by their cash flow conversion efficiency. Also see Xenetic Biosciences Inc market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
C&C Group plc
LSE:CCR
|
0.072x |
|
Whitebark Energy Ltd
AU:WBE
|
0.308x |
|
Eversafe Rubber Bhd
KLSE:0190
|
0.069x |
|
Novakand Pharma AB (publ)
ST:LARK
|
0.006x |
|
CARTIER SILVER CORP
F:2CI0
|
N/A |
|
Destiny Media Technologies Inc
V:DSY
|
0.158x |
|
Opyl Ltd
AU:OPL
|
1.994x |
|
THOR MNG CUFS/1LS- 00001
F:T5MB
|
N/A |
Annual Cash Flow Conversion Efficiency for Xenetic Biosciences Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Xenetic Biosciences Inc from 2012 to 2025. Review Xenetic Biosciences Inc free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $7.40 Million | $-2.29 Million | -0.309x | +34.08% |
| 2024-12-31 | $6.01 Million | $-2.82 Million | -0.469x | -11.67% |
| 2023-12-31 | $9.80 Million | $-4.11 Million | -0.420x | -23.35% |
| 2022-12-31 | $13.65 Million | $-4.65 Million | -0.340x | -32.19% |
| 2021-12-31 | $18.39 Million | $-4.74 Million | -0.258x | +26.26% |
| 2020-12-31 | $12.22 Million | $-4.27 Million | -0.349x | +6.04% |
| 2019-12-31 | $17.21 Million | $-6.40 Million | -0.372x | +42.99% |
| 2018-12-31 | $9.91 Million | $-6.46 Million | -0.652x | -724.13% |
| 2017-12-31 | $14.30 Million | $1.49 Million | 0.104x | +119.23% |
| 2016-12-31 | $16.17 Million | $-8.79 Million | -0.543x | +32.25% |
| 2015-12-31 | $6.61 Million | $-5.30 Million | -0.802x | +31.82% |
| 2014-12-31 | $10.48 Million | $-12.33 Million | -1.176x | -145.26% |
| 2013-12-31 | $12.62 Million | $-6.05 Million | -0.480x | -59.16% |
| 2012-12-31 | $20.78 Million | $-6.26 Million | -0.301x | -- |
About Xenetic Biosciences Inc
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance. The company's product pipeline includes XBIO-015 for the treatmen… Read more